ScinoPharm Taiwan Ltd 2013 SR
The report covers ScinoPharm's sustainability performance from 2011 to 2013, marking its first CSR publication. Key highlights include achieving record consolidated revenues of 5,088 million TWD in 2013 and being the first biotech company added to the MSCI Taiwan Index. The company implemented significant energy-saving measures, such as replacing oil-fired boilers with gas boilers, which reduced annual CO2 emissions by over 60%. ScinoPharm also maintained a strong focus on workplace safety, adhering to TOSHMS and Responsible Care standards, and achieved a high employee education level with 92% holding bachelor's degrees or higher.
Company: ScinoPharm Taiwan Ltd
Sector: Manufacturing
Country: Taiwan
Year: 2013
Type: SR
Pages: 29
Back to company
ScinoPharm Taiwan Ltd
Corporate Social Responsibility Report
The report covers ScinoPharm's sustainability performance from 2011 to 2013, marking its first CSR publication. Key highlights include achieving record consolidated revenues of 5,088 million TWD in 2013 and being the first biotech company added to the MSCI Taiwan Index. The company implemented significant energy-saving measures, such as replacing oil-fired boilers with gas boilers, which reduced annual CO2 emissions by over 60%. ScinoPharm also maintained a strong focus on workplace safety, adhering to TOSHMS and Responsible Care standards, and achieved a high employee education level with 92% holding bachelor's degrees or higher.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2011 - Dec 31, 2013
Fiscal Year
2013
Published
Dec 1, 2014
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Women in Management
Employees